PIK3CA and colorectal carcinoma: In this retrospective cohort study, patterns of intrinsic and acquired resistance in patients with BRAFV600E mutated metastatic CRC treated with double or triple combinations of inhibitors of the MAPK and PI3K pathways were observed.